RT Journal Article
SR Electronic
T1 Data Resource Profile: thousands of circulating RNA profiles of pre-clinical samples from the Janus Serum Bank Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.20243154
DO 10.1101/2021.01.22.20243154
A1 Langseth, Hilde
A1 Umu, Sinan Ugur
A1 Bucher-Johannessen, Cecilie
A1 Babigumira, Ronnie
A1 Leithaug, Magnus
A1 Lauritzen, Marianne
A1 Vineis, Paolo
A1 Ursin, Giske
A1 Lyle, Robert
A1 Rounge, Trine B
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.22.20243154.abstract
AB There is justified optimism regarding the use of miRNAs as early detection biomarkers of cancer. They are well characterized and are involved in all the hallmarks of cancer. Less is known about the role of most other non-coding RNA (ncRNAs) classes in normal physiology and tumorigenesis. The JanusRNA dataset consist of circulating RNA profiles of pre-clinical samples from 1631 cancer patients and 673 cancer-free controls. We studied eight cancer types including cancer of the: lung, colon, rectum, prostate, breast, testis, ovaries and gallbladder. JanusRNA has its origin from the large population-based Janus Serum Bank Cohort which consists of 318 628 Norwegians. The dataset combines information from the complete nationwide cancer registry, RNA sequencing profiles from 1631 cancer patients and 673 cancer-free controls, as well as data on lifestyle, anthropometry and biochemical measurements from national health surveys. The Janus Serum Bank is specifically suited for studies of early detection and risk biomarkers of cancer, since samples are collected nationwide over a large time span, pre-clinically and cancer occurs at different points in time after blood draw. We used a nested case-control design, selecting both cases and controls among the Janus cohort members. We restricted our selection to cases with at least one sample collected within 10 years prior to cancer diagnosis. We selected 673 cancer-free Janus participants for comparison of RNA levels with the cancer cases. The controls were frequency matched to the case group on sex, age at blood donation and date of blood donation. The JanusRNA dataset has been used to investigate the natural variation of circulating RNAs in cancer-free individuals. This data resource was also used in a study of variation in RNA expression associated with common traits like age, sex, smoking, BMI and physical activity in cancer-free individuals. RNA dynamics in lung and testicular carcinogenesis throughout a 10-year follow-up has also been studied.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was funded by the Research Council of Norway under the Program: Human Biobanks and Health data project numbers: 229621/H10 and 24879/H10 (production of sequencing data from cases with cancer of the lung colon rectum breast prostate ovaries and the main part of controls). Sequencing costs for the testicular cancer cases and a small number extra controls were covered by the Norwegian Cancer Society (grant number 190157 2017) and sequencing costs for the gallbladder cases were supported by the European Union within the initiative Biobanking and Biomolecular Research Infrastructure Large Prospective Cohorts Collaborative study Identification of biomarkers for gallbladder cancer risk prediction Towards personalized prevention of an orphan disease) under grant agreement no. 313010 (BBMRI LPC) and the German Federal Ministry of Education and Research (BMBF grant 01DN15021). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The JanusRNA study was approved by the regional committee for medical and health research ethics, Oslo, Norway (2016/1290) and (2013/1821), and is based on a broad consent from participants in the Janus cohort.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe JanusRNA datasets generated for this article are not readily available because of the principles and conditions set out in articles 6 (1) (e) and 9 (2) (j) of the General Data Protection Regulation (GDPR). National legal basis as per the Regulations on population-based health surveys and ethical approval from the Norwegian Regional Committee for Medical and Health Research Ethics (REC) is also required. Requests to access the datasets should be directed to the corresponding authors.